ARTICLE | Company News
Cell Therapy, Daiichi Sankyo deal
May 23, 2016 7:00 AM UTC
Cell Therapy granted Daiichi Sankyo exclusive rights to develop and commercialize Heartcel allogeneic immunomodulatory progenitor (iMP) cells in Japan. Cell Therapy received a L12.5 million ($17.9 mi...